SCHEMBL17455985

SCHEMBL17455985

Fc1ccc(OC2CCN(Cc3ccccc3)CC2)c(-c2ccncc2)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CYP11B1 P15538 1/20 0.48
▸ CYP11B2 P19099 1/20 0.48
▸ CCNT1 O60563 2/20 0.47
▸ CDK9 P50750 2/20 0.47
▸ SCN9A Q15858 1/20 0.46
▸ SCN8A Q9UQD0 3/20 0.45
▸ SCN1A P35498 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ ROCK1 Q13464 2/20 0.44
▸ ROCK2 O75116 1/20 0.43
▸ CCR2 P41597 1/20 0.43
▸ BCHE P06276 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ BACE1 P56817 1/20 0.43
▸ NMT1 P30419 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455972 0.94 MCHR1 (0.50) SMN1; SMN2CYP11B1CYP11B2CCNT1CDK9
SCHEMBL17455994 0.92 CYP11B1 (0.55) SMN1; SMN2CYP11B1CYP11B2SCN9ASCN8A
SCHEMBL17455938 0.90 SMN1; SMN2 (0.57) SMN1; SMN2SCN9AROCK1ROCK2CCR2
SCHEMBL17456041 0.86 CYP11B1 (0.53) SMN1; SMN2CYP11B1CYP11B2CCNT1CDK9
SCHEMBL17455920 0.81 CYP46A1 (0.57) SMN1; SMN2SCN9ASCN8ASCN1AROCK1
SCHEMBL17455967 0.81 SCN9A (0.51) SMN1; SMN2SCN9ASCN8AALDH1A1
SCHEMBL17455968 0.79 SMN1; SMN2 (0.53) SMN1; SMN2CYP11B1CYP11B2SCN9AALDH1A1
SCHEMBL17455988 0.77 KDM4E (0.46) SMN1; SMN2CYP11B1CYP11B2SCN9ASCN8A
SCHEMBL17456058 0.76 SCN9A (0.49) SMN1; SMN2SCN9A
SCHEMBL4125911 0.76 HRH3 (0.65) SMN1; SMN2SCN9AROCK1ROCK2CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 SMN1; SMN2 23/4885CYP11B1 88/4885CYP11B2 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback